cvncov vaccine
Vaccineexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
5
Phase 4
0
Earliest trial started Jun 18, 2020 (NCT04449276)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04838847 | Phase 3 | Oct 1, 2021 | CureVac AG |
| NCT04848467 | Phase 3 | Oct 1, 2021 | Bayer, CureVac AG |
| NCT04860258 | Phase 3 | Apr 22, 2021 | CureVac AG |
| NCT04674189 | Phase 3 | Dec 16, 2020 | CureVac AG |
| NCT04652102 | Phase 2/Phase 3 (Phase 3) | Dec 14, 2020 | CureVac AG |
| NCT04515147 | Phase 2 | Sep 28, 2020 | CureVac AG |
| NCT04449276 | Phase 1 | Jun 18, 2020 | Coalition for Epidemic Preparedness Innovations, CureVac AG |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CureVac AG | For profit | 7 | 6 | 3 | 2020 |
| Bayer | For profit | 1 | 1 | 1 | 2021 |
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1